{"id":523433,"date":"2025-08-29T00:00:00","date_gmt":"2025-08-29T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnecg0039-2025-biopharma-multiple-sclerosis-unmet-need-unmet-need-multiple-sclerosis-nonrelapsing-secondary\/"},"modified":"2026-03-31T10:25:09","modified_gmt":"2026-03-31T10:25:09","slug":"unnecg0039-2025-biopharma-multiple-sclerosis-unmet-need-unmet-need-multiple-sclerosis-nonrelapsing-secondary","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnecg0039-2025-biopharma-multiple-sclerosis-unmet-need-unmet-need-multiple-sclerosis-nonrelapsing-secondary\/","title":{"rendered":"Multiple Sclerosis &#8211; Unmet Need &#8211; Unmet Need &#8211; Multiple Sclerosis: Nonrelapsing Secondary-Progressive Multiple Sclerosis (US\/EU)"},"content":{"rendered":"<p>No treatments are approved for nonrelapsing secondary-progressive multiple sclerosis (nrSP-MS), an <abbr data-abbreviation-entity=\"4900\" title=\"multiple sclerosis\">MS<\/abbr> disease course in which physical disability accumulates in the absence of superimposed relapses through mechanisms that could entail diffuse inflammatory processes in the <abbr data-abbreviation-entity=\"4768\" title=\"central nervous system\">CNS<\/abbr> (i.e., smoldering <abbr data-abbreviation-entity=\"4900\" title=\"multiple sclerosis\">MS<\/abbr>). Although nrSP-MS patients may receive an approved <abbr data-abbreviation-entity=\"4900\" title=\"multiple sclerosis\">MS<\/abbr> disease modifying therapy (<abbr data-abbreviation-entity=\"5066\" title=\"disease-modifying therapy\">DMT<\/abbr>) off-label, management of these patients remains an area of high unmet need. Recently, Sanofi\u2019s oral Bruton\u2019s tyrosine kinase inhibitor tolebrutinib achieved the primary endpoint in the Phase 3 HERCULES trial in nrSP-MS, significantly reducing confirmed disability progression compared with placebo, and other agents in late-phase development are being tested in this population. This report will examine neurologists\u2019 satisfaction with <abbr data-abbreviation-entity=\"5066\" title=\"disease-modifying therapy\">DMT<\/abbr>s used off-label today in nrSP-MS and gauge the opportunity and value-drivers for alternatives to treat this underserved <abbr data-abbreviation-entity=\"4900\" title=\"multiple sclerosis\">MS<\/abbr> subpopulation.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>Which clinical attributes are the key drivers of prescribing decisions in nrSP-MS and which <abbr data-abbreviation-entity=\"5066\" title=\"disease-modifying therapy\">DMT<\/abbr>s used off-label are the best current performers?<\/li>\n<li>Which clinical attributes hold the highest level of need for improved treatment options in nrSP-MS?<\/li>\n<li>Based on conjoint analysis and <abbr data-abbreviation-entity=\"6194\" title=\"Target Product Profile\">TPP<\/abbr> simulation, what trade-offs among efficacy, safety, and price are neurologists willing to make for a hypothetical new drug to treat nonrelapsing <abbr data-abbreviation-entity=\"4962\" title=\"secondary-progressive multiple sclerosis\">SP-MS<\/abbr>?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><a>Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:<\/a><\/p>\n<ul class=\"round-bullets\">\n<li>Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians\u2019 weightings and analysis of stated vs. derived importance.<\/li>\n<li>Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.<\/li>\n<li>Analyze market scenarios for different target product profiles using the <abbr data-abbreviation-entity=\"6194\" title=\"Target Product Profile\">TPP<\/abbr> Simulator.<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States, United Kingdom, France, Germany<\/p>\n<p><strong>Primary research: <\/strong>Survey of 61 U.S. and 30 European neurologists fielded in July\u00a02025<\/p>\n<p><strong>Key companies:<\/strong> TG Therapeutics \/ Neuraxpharm, Novartis, Merck KGaA \/ EMD Serono, Roche \/ Genentech, Biogen, Sanofi<\/p>\n<p><strong>Key drugs:<\/strong> Briumvi, Kesimpta, Mavenclad, Mayzent, Ocrevus, teriflunomide, Tysabri, tolebrutinib, frexalimab<\/p>\n","protected":false},"template":"","class_list":["post-523433","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-multiple-sclerosis","biopharma-therapy-areas-neurology","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/523433","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/523433\/revisions"}],"predecessor-version":[{"id":523697,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/523433\/revisions\/523697"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=523433"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}